Prescribed by hematologists/oncologists for adult patients with: 🔹 Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL): Both first-line and relapsed/refractory cases. 🔹 Mantle Cell Lymphoma (MCL): For patients who have received at least one prior therapy. 🔹 Waldenström's Macroglobulinemia (WM). 🔹 Chronic Graft-Versus-Host Disease (cGVHD): After failure of systemic therapy.

Dosage and administration

Sales Unit: Bottle containing 120 capsules (140 mg strength). ⚠️ APPLICATION INSTRUCTIONS: Dosage: Typically 420 mg (3 capsules) for CLL/WM or 560 mg (4 capsules) for MCL, taken once daily. Follow your doctor's exact prescription. Administration: Swallow capsules whole with a glass of water. Do not open, break, or chew. Take at the same time each day. Dietary Warning: Avoid grapefruit and Seville oranges, as they can dangerously increase the drug level in your blood. ✋ Surgery: Must be stopped 3-7 days before any surgery or dental procedure due to bleeding risk.

⛔ Pregnancy & Breastfeeding: Strictly contraindicated. Hypersensitivity to Ibrutinib. Severe hepatic (liver) impairment. Children (under 18 years). Concomitant use with strong CYP3A inhibitors or preparations containing St. John's Wort.

Monitoring for bleeding and heart rhythm is essential. Potential side effects: 🩸 Hemorrhage: Bruising, nosebleeds, or prolonged bleeding from minor cuts. ❤️ Cardiac: Atrial fibrillation or flutter (irregular heartbeat). 🦠 Infections: Increased risk of upper respiratory tract infections. 🤢 Digestive: Diarrhea (very common), nausea. Hydration is key.

Ibrutinix — Ibrutinib 140 mg, 120 product-page.units_short, Everest

100% original product

Active ingredient

Ibrutinib

Manufacturer

Everest

Dosage 140 mg

Dosage form Capsules

Capsules per pack 120

Ibrutinix Capsules — Ibrutinib 140 mg (120 Caps) Everest

Name: Ibrutinix
Brand: Everest
SKU: PROD-199
Price: 25599 UAH
Availability: InStock

25599₴ ~~27769₴~~ -8%

Ibrutinix 140 mg (Ibrutinib) is a targeted therapy drug, a Bruton's tyrosine kinase (BTK) inhibitor, and a generic equivalent to Imbruvica. It works by blocking specific chemical signals that cancer cells use to grow and survive.

Manufacturer: Everest Pharmaceuticals (Bangladesh). Ibrutinib represents a major breakthrough in treating B-cell malignancies without traditional chemotherapy.

Key Features:

✅ Mechanism: Irreversibly binds to the BTK protein, inhibiting the proliferation of malignant B-cells.
✅ Broad Application: Effective across several types of blood cancers, including CLL and Mantle Cell Lymphoma.
✅ Oral Therapy: Convenient once-daily capsule administration.

Prescribed by hematologists/oncologists for adult patients with:

🔹 Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL): Both first-line and relapsed/refractory cases.
🔹 Mantle Cell Lymphoma (MCL): For patients who have received at least one prior therapy.
🔹 Waldenström's Macroglobulinemia (WM).
🔹 Chronic Graft-Versus-Host Disease (cGVHD): After failure of systemic therapy.

Sales Unit: Bottle containing 120 capsules (140 mg strength).

⚠️ APPLICATION INSTRUCTIONS:

Dosage: Typically 420 mg (3 capsules) for CLL/WM or 560 mg (4 capsules) for MCL, taken once daily. Follow your doctor's exact prescription.
Administration: Swallow capsules whole with a glass of water. Do not open, break, or chew. Take at the same time each day.
Dietary Warning: Avoid grapefruit and Seville oranges, as they can dangerously increase the drug level in your blood.
✋ Surgery: Must be stopped 3-7 days before any surgery or dental procedure due to bleeding risk.

⛔ Pregnancy & Breastfeeding: Strictly contraindicated.
Hypersensitivity to Ibrutinib.
Severe hepatic (liver) impairment.
Children (under 18 years).
Concomitant use with strong CYP3A inhibitors or preparations containing St. John's Wort.